Neurodegenerative disease Archives

News and Trends 28 Nov 2017

New Gene Therapy for Parkinson’s will be Developed in the UK

Synpromics and UCL will collaborate to develop a gene therapy to treat Parkinson’s disease that only targets specific neurons involved in the disease. Synpromics, based in Edinburgh, Scotland, is a company focusing on gene control. The biotech has decided to put its technology to use for the development of a gene therapy for Parkinson’s in […]

November 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Nov 2017

Finnish Scientists Find Brain Cells Involved in Alzheimer’s Disease

Alzheimer’s disease is rapidly increasing in prevalence but we have no effective treatment. But, Finnish Researchers have found a new target to investigate. Researchers at the University of East Finland have found that astrocytes, the cells that support the brain, could play a major role in the pathogenesis of Alzheimer’s disease. The research, published in […]

November 22, 2017 - 3 minutesmins - By Alex Dale

hummingbird diagnostics cancer alzheimer parkinson

News and Trends 16 Nov 2017

German Diagnostics Firm Tackles Early Detection of Cancer, Alzheimer’s and Parkinson’s

Hummingbird Diagnostics has teamed up with Saarland University to develop molecular diagnostics that can detect serious diseases early using blood samples. Based in Heidelberg, Germany, Hummingbird Diagnostics develops early diagnostics in multiple disease areas, ranging from cancer to cardiovascular and neurodegenerative disease. Its technology is based in the detection of miRNA, molecules that are involved […]

November 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

neurimmune ono pharmaceutical neurodegenerative disease

More News! 9 Nov 2017

Swiss Biotech and Japanese Pharma Team Up to Tackle Neurodegenerative Disease

Neurimmune and Ono Pharmaceutical have partnered to develop an antibody drug against a still undisclosed neurodegenerative disease. Neurimmune has a new partner to help it develop treatments for neurodegenerative diseases. Ono Pharmaceutical will work together with the Swiss biotech to develop human antibodies against a new disease target that remains undisclosed for now. In exchange for an […]

November 9, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 2 Nov 2017

Swiss Biotech Gets €12M as its Alzheimer’s Candidate Enters Phase II

AC Immune’s Anti-Tau antibody for the treatment of Alzheimer’s disease has reached Phase II, prompting milestone payments from Genentech. Today, the first patient in a Phase II trial was dosed with AC Immune’s anti-Tau antibody for the treatment of Alzheimer’s disease. This triggered a milestone payment of CHF 14M (€12M) from its collaborator, Genentech, as part of an agreement […]

November 2, 2017 - 2 minutesmins - By Alex Dale

Theranexus IPO CNS Narcolepsy Parkinsons Alzheimers

News and Trends 30 Oct 2017

French Biotech Closes €19M IPO to Treat Narcolepsy and Alzheimer’s

Theranexus debuts on Euronext Paris raising €19.6M that will support the development of its pipeline of CNS drugs for narcolepsy, Parkinson’s, Alzheimer’s and neuropathic pain. Theranexus, based in Lyon, starts trading on Euronext Paris today. The company starts off with a market cap of €47.5M after closing a €19.6M IPO. With the money raised, the company […]

October 30, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

Interview 25 Oct 2017

What Could RNA Therapies Do for the Treatment of CNS Disorders?

Evelyn chatted with Thomas de Vlaam to find out what his company, Amylon, is working on and how it hopes to change the field fighting CNS disorders. De Vlaam came up with AT-010, a drug candidate for the treatment of Katwijk‘s disease, during his time at ProQR. When it became clear that he had something […]

October 25, 2017 - 3 minutesmins - By Alex Dale

News and Trends 16 Oct 2017

German Drug to Stop the Progression of Alzheimer’s Enters Phase IIb

Probiodrug is ready to start a Phase IIb trial with an Alzheimer’s drug that prevents the formation of Aβ plaques before the disease progresses. The German biotech Probiodrug is getting ready to start two Phase II trials to study the safety and efficacy of its candidate PQ912, a drug designed to intervene in the early stages of […]

October 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Startup Scout 13 Oct 2017

This French Biotech is Taking On CNS Diseases of the Young and the Elderly

This week we’re in Castres in the South of France to visit Neurolixis. This biotech is taking on diseases of the CNS, such as Parkinson’s, depression and schizophrenia. Mission: Neurolixis is tackling CNS and mood diseases, a number of which lack effective treatment options at the moment. The biotech currently has two candidate drugs undergoing […]

October 13, 2017 - 2 minutesmins - By Alex Dale

News and Trends 11 Oct 2017

Scottish Scientists Could Hold the Key to Unlocking Parkinson’s Disease

A decade of work has culminated in researchers reconstructing a protein that is key to defending the brain against Parkinson’s disease. Researchers at the University of Dundee have made a breakthrough by uncovering the 3D structure of an enzyme, PINK1, that can protect the brain against Parkinson’s disease. The disease is characterised by the degeneration […]

October 11, 2017 - 3 minutesmins - By Alex Dale

More News! 19 Sep 2017

Scottish Scientists Claim that the Genome Controls the Aging of the Brain

Scientists in Scotland claim gene expression in the brain is so precisely controlled that they could predict your age just by looking at your genome. Researchers at the University of Edinburgh believe that genes in the brain are expressed at very specific times during a person’s life to carry out particular functions. Changes were seen […]

September 19, 2017 - 2 minutesmins - By Alex Dale

Allergan Heptares Therapeutics alzheimers

News and Trends 1 Sep 2017

Allergan Takes to the Clinic a New Alzheimer’s Drug from a €3Bn Deal

Allergan’s partner Heptares Therapeutics has dosed the first patient with a GPCR drug to treat major symptoms of Alzheimer’s disease. A year ago, Allergan signed a massive deal of up to €3Bn with Heptares Therapeutics for the development of drugs that target G-protein-coupled receptors (GPCRs), a protein superfamily that currently comprises the target of around […]

September 1, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Neurodegenerative disease

New Gene Therapy for Parkinson’s will be Developed in the UK

Finnish Scientists Find Brain Cells Involved in Alzheimer’s Disease

German Diagnostics Firm Tackles Early Detection of Cancer, Alzheimer’s and Parkinson’s

Swiss Biotech and Japanese Pharma Team Up to Tackle Neurodegenerative Disease

Swiss Biotech Gets €12M as its Alzheimer’s Candidate Enters Phase II

French Biotech Closes €19M IPO to Treat Narcolepsy and Alzheimer’s

What Could RNA Therapies Do for the Treatment of CNS Disorders?

German Drug to Stop the Progression of Alzheimer’s Enters Phase IIb

This French Biotech is Taking On CNS Diseases of the Young and the Elderly

Scottish Scientists Could Hold the Key to Unlocking Parkinson’s Disease

Scottish Scientists Claim that the Genome Controls the Aging of the Brain

Allergan Takes to the Clinic a New Alzheimer’s Drug from a €3Bn Deal

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!